

Claudia Balducci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4249131/publications.pdf>

Version: 2024-02-01

62
papers

3,765
citations

109311

35
h-index

128286

60
g-index

66
all docs

66
docs citations

66
times ranked

5507
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthetic amyloid- β oligomers impair long-term memory independently of cellular prion protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 2295-2300.	7.1	435
2	Reduced anxiety and improved stress coping ability in mice lacking NPY β 2 receptors. <i>European Journal of Neuroscience</i> , 2003, 18, 143-148.	2.6	173
3	Dissociable Contribution of 5-HT1A and 5-HT2A Receptors in the Medial Prefrontal Cortex to Different Aspects of Executive Control such as Impulsivity and Compulsive Perseveration in Rats. <i>Neuropsychopharmacology</i> , 2006, 31, 757-767.	5.4	162
4	An N-terminal Fragment of the Prion Protein Binds to Amyloid- β Oligomers and Inhibits Their Neurotoxicity in Vivo. <i>Journal of Biological Chemistry</i> , 2013, 288, 7857-7866.	3.4	162
5	Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. <i>Brain</i> , 2008, 131, 1506-1515.	7.6	146
6	Multifunctional Liposomes Reduce Brain β -Amyloid Burden and Ameliorate Memory Impairment in Alzheimer's Disease Mouse Models. <i>Journal of Neuroscience</i> , 2014, 34, 14022-14031.	3.6	141
7	Alzheimer's Disease, Oligomers, and Inflammation. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1261-1276.	2.6	141
8	Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by β -amyloid oligomers in an acute mouse model of Alzheimer's disease. <i>Brain, Behavior, and Immunity</i> , 2017, 60, 188-197.	4.1	123
9	Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 609-618.	3.3	109
10	Mutant Prion Protein Expression Causes Motor and Memory Deficits and Abnormal Sleep Patterns in a Transgenic Mouse Model. <i>Neuron</i> , 2008, 60, 598-609.	8.1	97
11	Neuroinflammation and the Gut Microbiota: Possible Alternative Therapeutic Targets to Counteract Alzheimer's Disease?. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 284.	3.4	95
12	The Serotonin 5-HT2A Receptors Antagonist M100907 Prevents Impairment in Attentional Performance by NMDA Receptor Blockade in the Rat Prefrontal Cortex. <i>Neuropsychopharmacology</i> , 2004, 29, 1637-1647.	5.4	89
13	Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases. <i>Movement Disorders</i> , 2016, 31, 771-781.	3.9	88
14	Time-dependent induction of angiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat. <i>Psychopharmacology</i> , 2002, 160, 113-121.	3.1	75
15	c-Jun N-terminal Kinase Regulates Soluble β Oligomers and Cognitive Impairment in AD Mouse Model. <i>Journal of Biological Chemistry</i> , 2011, 286, 43871-43880.	3.4	74
16	Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimer's disease. <i>Brain</i> , 2010, 133, 3323-3335.	7.6	71
17	APP Transgenic Mice: Their Use and Limitations. <i>NeuroMolecular Medicine</i> , 2011, 13, 117-137.	3.4	69
18	Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer's mice. <i>Cell Death and Differentiation</i> , 2021, 28, 203-218.	11.2	63

#	ARTICLE	IF	CITATIONS
19	Anticonvulsant effects and behavioural outcomes of rAAV serotype 1 vector-mediated neuropeptide Y overexpression in rat hippocampus. <i>Gene Therapy</i> , 2010, 17, 643-652.	4.5	62
20	Transgenic Fatal Familial Insomnia Mice Indicate Prion Infectivity-Independent Mechanisms of Pathogenesis and Phenotypic Expression of Disease. <i>PLoS Pathogens</i> , 2015, 11, e1004796.	4.7	61
21	Doxycycline for Alzheimer's Disease: Fighting β -Amyloid Oligomers and Neuroinflammation. <i>Frontiers in Pharmacology</i> , 2019, 10, 738.	3.5	58
22	Exploring Alzheimer's disease mouse brain through X-ray phase contrast tomography: From the cell to the organ. <i>NeuroImage</i> , 2019, 184, 490-495.	4.2	56
23	NPY gene transfer in the hippocampus attenuates synaptic plasticity and learning. <i>Hippocampus</i> , 2008, 18, 564-574.	1.9	55
24	Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2. <i>Brain, Behavior, and Immunity</i> , 2018, 69, 591-602.	4.1	55
25	The β -Secretase Modulator CHF5074 Restores Memory and Hippocampal Synaptic Plasticity in Plaque-Free Tg2576 Mice. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 799-816.	2.6	53
26	In Vivo Application of beta Amyloid Oligomers: A Simple Tool to Evaluate Mechanisms of Action and New Therapeutic Approaches. <i>Current Pharmaceutical Design</i> , 2014, 20, 2491-2505.	1.9	53
27	Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models. <i>Neurobiology of Aging</i> , 2018, 70, 128-139.	3.1	52
28	Dextromethorphan reduces intravenous cocaine self-administration in the rat. <i>European Journal of Pharmacology</i> , 1997, 321, 279-283.	3.5	51
29	Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's $A\beta$ peptide. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 723-732.	3.3	47
30	WAY 100635, a 5-HT _{1A} receptor antagonist, prevents the impairment of spatial learning caused by blockade of hippocampal NMDA receptors. <i>Neuropharmacology</i> , 1999, 38, 1165-1173.	4.1	46
31	Novel targets in Alzheimer's disease: A special focus on microglia. <i>Pharmacological Research</i> , 2018, 130, 402-413.	7.1	46
32	Plasma and Brain Concentrations of Doxycycline after Single and Repeated Doses in Wild-Type and APP23 Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 368, 32-40.	2.5	46
33	S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT _{1A} receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. <i>British Journal of Pharmacology</i> , 1999, 128, 1207-1214.	5.4	41
34	Multifunctional liposomes delay phenotype progression and prevent memory impairment in a presymptomatic stage mouse model of Alzheimer disease. <i>Journal of Controlled Release</i> , 2017, 258, 121-129.	9.9	40
35	Cellular prion protein neither binds to alpha-synuclein oligomers nor mediates their detrimental effects. <i>Brain</i> , 2019, 142, 249-254.	7.6	38
36	Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington's Disease. <i>Molecular Neurobiology</i> , 2020, 57, 1889-1903.	4.0	38

#	ARTICLE	IF	CITATIONS
37	Reversal of visual attention dysfunction after AMPA lesions of the nucleus basalis magnocellularis (NBM) by the cholinesterase inhibitor donepezil and by a 5-HT1A receptor antagonist WAY100635. <i>Psychopharmacology</i> , 2003, 167, 28-36.	3.1	37
38	Cognitive Deficits Associated with Alteration of Synaptic Metaplasticity Precede Plaque Deposition in A β PP23 Transgenic Mice. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 1367-1381.	2.6	35
39	Low doses of 8-OH-DPAT prevent the impairment of spatial learning caused by intrahippocampal scopolamine through 5-HT1A receptors in the dorsal raphe. <i>British Journal of Pharmacology</i> , 2000, 131, 375-381.	5.4	34
40	Inhibition of Nitric Oxide Synthesis Reduces Intravenous Cocaine Self-administration in the Rat. <i>Neuropharmacology</i> , 1996, 35, 1811-1814.	4.1	32
41	Neuropeptide Y Overexpression Using Recombinant Adenoassociated Viral Vectors. <i>Neurotherapeutics</i> , 2009, 6, 300-306.	4.4	32
42	A critical appraisal of tau-targeting therapies for primary and secondary tauopathies. <i>Alzheimer's and Dementia</i> , 2022, 18, 1008-1037.	0.8	29
43	The Continuing Failure of Bexarotene in Alzheimer's Disease Mice. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 471-482.	2.6	28
44	Stimulation of 5-HT 1A receptors in the dorsal raphe ameliorates the impairment of spatial learning caused by intrahippocampal 7-chloro-kynurenic acid in naive and pretrained rats. <i>Psychopharmacology</i> , 2001, 158, 39-47.	3.1	26
45	Dopamine partial receptor agonists reduce ethanol intake in the rat. <i>European Journal of Pharmacology</i> , 1996, 296, 233-238.	3.5	25
46	Striatum and entorhinal cortex atrophy in AD mouse models: MRI comprehensive analysis. <i>Neurobiology of Aging</i> , 2015, 36, 776-788.	3.1	25
47	Flavonoid-Derived Human Phenylacetylvalerolactone Metabolites Selectively Detoxify Amyloid β Oligomers and Prevent Memory Impairment in a Mouse Model of Alzheimer's Disease. <i>Molecular Nutrition and Food Research</i> , 2020, 64, e1900890.	3.3	24
48	Biophysical and in Vivo Studies Identify a New Natural-Based Polyphenol, Counteracting A β Oligomerization in Vitro and A β Oligomer-Mediated Memory Impairment and Neuroinflammation in an Acute Mouse Model of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2019, 10, 4462-4475.	3.5	23
49	β -amyloid oligomers and prion protein. <i>Prion</i> , 2011, 5, 10-15.	1.8	22
50	A Rational Structured Epitope Defines a Distinct Subclass of Toxic Amyloid-beta Oligomers. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1591-1606.	3.5	21
51	Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight. <i>Progress in Molecular Biology and Translational Science</i> , 2021, 177, 175-202.	1.7	21
52	Assessment of plaque morphology in Alzheimer's mouse cerebellum using three-dimensional X-ray phase-based virtual histology. <i>Scientific Reports</i> , 2020, 10, 11233.	3.3	19
53	The development of ADAM10 endocytosis inhibitors for the treatment of Alzheimer's disease. <i>Molecular Therapy</i> , 2022, 30, 2474-2490.	8.2	15
54	Pulmonary administration of functionalized nanoparticles significantly reduces beta-amyloid in the brain of an Alzheimer's disease murine model. <i>Nano Research</i> , 2016, 9, 2190-2201.	10.4	13

#	ARTICLE	IF	CITATIONS
55	Gamma-Hydroxybutyric Acid Decreases Intravenous Cocaine Self-Administration in Rats. <i>Pharmacology Biochemistry and Behavior</i> , 1998, 59, 697-702.	2.9	12
56	The neurodegeneration in Alzheimer disease and the prion protein. <i>Prion</i> , 2013, 7, 60-65.	1.8	12
57	The Anti-Prion Antibody 15B3 Detects Toxic Amyloid- β^2 Oligomers. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1485-1497.	2.6	12
58	X-ray Phase Contrast Tomography Serves Preclinical Investigation of Neurodegenerative Diseases. <i>Frontiers in Neuroscience</i> , 2020, 14, 584161.	2.8	12
59	Accelerating Alzheimer's disease drug discovery and development: what's the way forward?. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 727-735.	5.0	9
60	Deletion of calcineurin from astrocytes reproduces proteome signature of Alzheimer's disease and epilepsy and predisposes to seizures. <i>Cell Calcium</i> , 2021, 100, 102480.	2.4	6
61	Sleep inhibition induced by amyloid- β^2 oligomers is mediated by the cellular prion protein. <i>Journal of Sleep Research</i> , 2021, 30, e13187.	3.2	5
62	Internalization of nanopolymeric tracers does not alter characteristics of placental cells. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 1036-1048.	3.6	4